Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that platelet-rich plasma therapy significantly increased hair diameter and density in male androgenetic alopecia patients over six months, particularly in those with AGA durations up to five years.

This study found that 58% of men aged 30-50 had androgenic alopecia, with disease severity increasing with age and many being candidates for medical treatment or hair transplantation.

This article reviews the classification history of androgenic alopecia and highlights the need for further research to find effective hair growth medications.

This study found that early-onset male androgenetic alopecia was associated with a higher prevalence of metabolic syndrome compared to age-matched controls.

This study found that 5% topical minoxidil was moderately more effective at increasing hair regrowth than 10% minoxidil and placebo in men with androgenetic alopecia.

This study found that platelet-rich plasma therapy was more effective in increasing hair count than topical 5% minoxidil lotion in men with androgenetic alopecia.

In this study, the Hamilton-Norwood subtype of female pattern hair loss was associated with early onset and polycystic ovary syndrome, while the Ludwig pattern was more common overall.

This study found that the prevalence of androgenetic alopecia in Chinese men and women was lower than in Caucasians and similar to that in Koreans.

This study found that the prevalence of androgenetic alopecia in Chinese men was lower than in Caucasian men, similar to Korean men, and most commonly presented as type III vertex.

This study discusses patterns of androgenetic alopecia in Indian men but reports no new clinical findings.

This study suggests the average age of onset for androgenic alopecia may be decreasing, but a longer-term study is needed to confirm this observation.

This study found that young males with stage III or higher androgenetic alopecia had higher insulin resistance and cardiovascular-related features, suggesting the need for metabolic assessment in this population.

This study assessed the use of oral finasteride in transgender men with androgenetic alopecia and found that all patients improved by one grade on the Norwood–Hamilton scale within about 5.5 months, with no significant adverse effects reported during the 16.2 months of follow-up.

This study found that androgenic alopecia was associated with a decreased risk of testicular germ cell tumors but a potential increased risk of high-grade prostate cancer.

This study supports evaluating metabolic syndrome and insulin resistance in young males with advanced androgenic alopecia to potentially reduce future cardiovascular and type 2 diabetes risks.

This study found that males with androgenetic alopecia had a higher risk of coronary artery disease, with significant differences in several lipid and blood pressure markers compared to controls.

This study found that a genetic test using 5 to 20 SNPs can predict male pattern baldness with variable accuracy in European men, especially those aged 50 and older.

This study, conducted among Egyptians, found a borderline significant association between the Stul polymorphism of the androgen receptor gene and androgenetic alopecia in males, with higher androgen receptor expression in balding scalp areas.

This review discusses female androgenic alopecia, highlighting its potential difference from male androgenic alopecia and notes increased incidence, but reports no new clinical findings.

This case report describes a 21-year-old man with alopecia areata presenting as a U-shaped hair loss pattern resembling Hamilton grade VII male-pattern baldness, with no signs of inflammation or related conditions.

This study observed that among men aged 18 to 35 with early onset androgenetic alopecia, those with severe grades and metabolic syndrome may face increased cardiovascular risks, highlighting the importance of screening and monitoring.

In this study, injecting two different concentrations of botulinum toxin A was found to be safe and effective for treating androgenetic alopecia in Egyptian men and women, with improvements in hair grade and vellus hair density observed over six months.

This study found that androgenetic alopecia can affect the occipital region in men with advanced stages of the condition.

This study found that androgenetic alopecia may be a predictor of metabolic syndrome, emphasizing the importance of screening patients with severe hair loss for related health risks.

This study found that trichoscopy revealed significant differences in certain variables, such as the brown peripilar sign and white peripilar sign, which may aid in diagnosing early and late stages of androgenetic alopecia.

In this study, researchers reported that androgenetic alopecia is associated with significantly decreased quality of life, particularly impacting younger patients and those with severe or long-standing hair loss.

This study found that dutasteride mesotherapy increased the diameter of existing hair in five Mexican men with androgenetic alopecia, without reported side effects.

This pilot study found that a novel regimen including NuH Hair led to significant hair growth in male patients with androgenic alopecia, regardless of atopy status, with quicker results when additional treatment components were used.

This study found that patients with chronic kidney disease-associated pruritus had elevated serum levels of interleukin 31, suggesting a possible role of this cytokine in the condition.

In this study, the prevalence of androgenetic alopecia among Korean men and women was found to be lower than in caucasians, with Korean men showing more frontal hairline preservation and a higher incidence of 'female pattern' hair thinning.